Metabolic Solutions Development
MSDC is a drug discovery and development company investigating new molecular targets and developing novel therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially insulin resistance and type 2 diabetes. The company's mission is to develop drugs that will have positive effects on healthcare outcomes, focusing on innovative treatments for metabolic diseases, neurodegeneration, and related conditions.
Industries
Nr. of Employees
small (1-50)
Metabolic Solutions Development
Patents
Products
MSDC-0160
Oral small-molecule modulator of a mitochondrial protein complex developed as an insulin sensitizer and investigated for neurodegenerative and metabolic indications; studied in Phase 2a trials in Alzheimer’s disease and a Phase 2b study in type 2 diabetes.
MSDC-0602 / MSDC-0602K (clinical development program)
Oral small-molecule insulin-sensitizing compound developed for metabolic liver disease (NASH) and type 2 diabetes; advanced into randomized Phase 2 clinical evaluation (EMMINENCE trial for NASH).
MSDC-0160
Oral small-molecule modulator of a mitochondrial protein complex developed as an insulin sensitizer and investigated for neurodegenerative and metabolic indications; studied in Phase 2a trials in Alzheimer’s disease and a Phase 2b study in type 2 diabetes.
MSDC-0602 / MSDC-0602K (clinical development program)
Oral small-molecule insulin-sensitizing compound developed for metabolic liver disease (NASH) and type 2 diabetes; advanced into randomized Phase 2 clinical evaluation (EMMINENCE trial for NASH).
Expertise Areas
- Clinical trial management
- Small-molecule therapeutics development
- Mitochondrial-targeted drug discovery
- Translational medicine and biomarker development
Key Technologies
- Photoaffinity labeling and radioligand binding
- Protein purification and recombinant expression
- Gene knockdown experiments
- Metabolomics